Lofexidine Side Effects
For the Consumer
Applies to lofexidine: oral tablets
Side effects include:
For Healthcare Professionals
Applies to lofexidine: oral tablet
The more commonly reported adverse effects have included orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth.[Ref]
Adverse reactions are reported at mean average daily doses up to 2.88 mg/day. With a mean dose of 2.16 mg/day, insomnia, orthostatic hypotension, bradycardia, and hypotension, were reported at 51%, 29%, 24%, and 30%, respectively. Syncope was reported in 0.9% of patients receiving 2.16 mg/day (1.4% for patients receiving 2.88 mg/day and 0% for placebo).
Blood pressure (BP) elevations of 140 mmHg (systolic) or higher, and above the subject's pretreatment BP, occurred in 39.7% (n= 23/58) of patients following discontinuation of a 5-day course of 2.88 mg/day. BP peaked on the second day after discontinuation.
Since market introduction (1992 in UK), there has been 1 case of QT prolongation, bradycardia, torsades de pointes, and cardiac arrest with successful resuscitation; there have been 3 reports of clinically significant QT prolongation in patients concomitantly receiving methadone.
Cardiac electrophysiology studies with single doses of 1.44 to 1.8 mg produced maximum mean change from baseline QTcF of 14.4 and 13.6 milliseconds, respectively in healthy normal volunteers. In a phase 3 study in opioid-dependent subjects, a maximal mean prolongation of the QTcF interval of 7.3 and 9.3 milliseconds occurred at doses of 2.16 and 2.88 mg/day respectively. In patients with renal or hepatic impairment, QT prolongation was reported; it was more pronounced in subjects with severe renal or hepatic impairment.
Very common (10% or more): Orthostatic hypotension (up to 42%); bradycardia (up to 32%); hypotension (30%), hypertension with abrupt discontinuation
Uncommon (0.1% to 1%): Syncope
Postmarketing reports: QT prolongation
Very common (10% or more): Dizziness (up to 23%), somnolence (up to 13%), sedation (up to 13%)
Very common (10% or more): Dry mouth (up to 11%)
Uncommon (0.1% to 1%): Tinnitus
Insomnia was reported in 51% of patients receiving a mean average daily dose of 2.16 mg/day and 55% of those receiving 2.88 mg/day; however, it was also reported by 48% of those receiving placebo.
Very common (10% or more): Insomnia (up to 55%)
Frequency not reported: Withdrawal symptoms
Frequently asked questions
- How do you get Lucemyra (lofexidine)?
- Is Lucemyra (lofexidine) a controlled drug?
- How long does it take to work?
More about lofexidine
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (35)
- Patient tips
- Compare alternatives
- En español
- Drug class: antiadrenergic agents, centrally acting
Related treatment guides
1. "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC (2018):
Some side effects may not be reported. You may report them to the FDA.